I'm LongbridgeAI, I can summarize articles.AbbVie (ABBV) rose 0.38% for the week to close at $256.46, versus a 0.09% gain for the S&P 500, outperforming the benchmark by about 0.29 percentage points. The week started at $254.17 on Monday, then climbed through Tuesday and Wednesday to $261.72. Thursday saw a new intraday high of $264.25 before fading to $260.21, and Friday extended the pullback to $256.46, leaving a rally-then-fade shape. Weekly amplitude was 4.69%, with average daily volume about 23.
The Week
AbbVie (ABBV) rose 0.38% for the week to close at $256.46, versus a 0.09% gain for the S&P 500, outperforming the benchmark by about 0.29 percentage points. The week started at $254.17 on Monday, then climbed through Tuesday and Wednesday to $261.72. Thursday saw a new intraday high of $264.25 before fading to $260.21, and Friday extended the pullback to $256.46, leaving a rally-then-fade shape. Weekly amplitude was 4.69%, with average daily volume about 23.57% below the 60-day median, so the advance lacked fresh volume support.
Key Events
AbbVie’s own pipeline and M&A dominated the news flow. On 3 September, it reported positive top-line data from the Phase 3 CERVINO trial, showing Etentamig led to significantly higher response rates and longer progression-free survival in patients with relapsed or refractory multiple myeloma; a later report cited a 74% response rate. The company also completed the acquisition of Apogee Therapeutics, which then moved toward delisting after a Nasdaq suspension. On 4 September, AbbVie issued fiscal 2026 earnings guidance. Broader industry noise included the disclosure of global pharma companies that had announced drug pricing agreements with the Trump administration, plus frequent biotech 52-week-high headlines. For ABBV, however, the core narrative was the trial readout and the closing of the Apogee deal.
Analyst Ratings
AbbVie is covered by 31 institutions in total: 17 rate it buy, 8 over, 5 hold and 1 under, with no sell or no-opinion ratings. The consensus rating is buy, and the consensus target price stands at $276.59, roughly 7.85% above the latest price. The target range is wide, from $200.00 to $328.00, pointing to real dispersion in valuation views. Within the biotech industry group of 507 names, AbbVie’s rating rank is 3rd, placing it among the more heavily endorsed coverage groups.
The Week Ahead
The clearest forward-looking threads come from the company’s own news: the FY 2026 guidance will need to be digested, and the CERVINO data may continue to shape the multiple myeloma narrative. The integration of Apogee after the completed acquisition is another line to watch. On the macro side, 10 September brings initial jobless claims, final-demand PPI and core PPI for the US, alongside a 10-year Treasury auction and existing home sales data; rate and inflation prints can shift how large-cap pharma valuations are treated across the market.
In Short
AbbVie edged above the market this week, but the intraweek fade shows sellers stepping in near the highs. The news flow leans constructive: a positive Phase 3 readout and a completed acquisition, while the consensus rating is buy with a target above spot. Set against that, average daily volume ran below the 60-day median, and the most recent session’s capital snapshot shows large-lot money as a net seller while small and medium lots were net buyers, suggesting low-conviction participation. With a high P/E and a weekly turnover rate of just 0.27%, the key variables ahead are the path of the FY 2026 earnings guidance, how the market prices the CERVINO data, and whether macro rate and inflation prints shift valuation layers.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.